Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report

被引：1

作者：

John, Alexius ^{[1
]}

Vick, Joanna ^{[1
]}

Sarker, Sarah ^{[1
]}

Middleton, Elizabeth ^{[1
]}

Cartwright, Elizabeth ^{[1
]}

Manickavasagar, Thubeena ^{[1
]}

McMahon, David ^{[1
]}

Tokaca, Nadza ^{[1
]}

Popat, Sanjay ^{[1
,2
]}

机构：

[1] Royal Marsden Hosp, Lung Unit, London SW3 6JJ, England

[2] Inst Canc Res, London, England

来源：

JTO CLINICAL AND RESEARCH REPORTS | 2024年 / 5卷 / 07期

关键词：

Adverse event; ALK; Lorlatinib; Non-small cell lung cancer; Psychosis; Case report;

D O I：

10.1016/j.jtocrr.2024.100689

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system-active ALK inhibitor. Manifestations may include psychotic, mood, speech, and cognitive symptoms. Current guidance recommends permanent discontinuation of lorlatinib in cases of grade IV NAEs. Here, we report a case of successful rechallenge of dose-reduced lorlatinib after recovery of grade IV psychosis in a patient with ALKpositive NSCLC. (c) 2024 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).

引用

页数：5

共 8 条

[1]

Center for Drug Evaluation and Research US Food and Drug Administration, Multi-discipline Review for Givlaari: Food and Drug Adminstration

[2] Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies [J].

Dagogo-Jack, Ibiayi ;

Abbattista, Antonello ;

Murphy, John F. ;

Krulewicz, Stan ;

Do, Andrew ;

Peterson, Jennifer ;

Lin, Jessica J. ;

Gainor, Justin F. ;

Messina, Rossella ;

Krueger, Elizabeth A. ;

Thurm, Holger ;

Yeap, Beow Y. .

JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) :67-78

[3] A pragmatic guide for management of adverse events associated with lorlatinib [J].

Liu, Geoffrey ;

Mazieres, Julien ;

Stratmann, Jan ;

Ou, Sai-Hong Ignatius ;

Mok, Tony ;

Grizzard, Mary ;

Goto, Yasushi ;

Felip, Enriqueta ;

Solomon, Benjamin J. ;

Bauer, Todd M. .

LUNG CANCER, 2024, 191

[4] Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners [J].

Reed, Mollie ;

Rosales, Aimee-Lauren S. ;

Chioda, Marc D. ;

Parker, Lindsey ;

Devgan, Geeta ;

Kettle, Jacob .

ADVANCES IN THERAPY, 2020, 37 (06) :3019-3030

[5] Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial [J].

Shaw, Alice T. ;

Felip, Enriqueta ;

Bauer, Todd M. ;

Besse, Benjamin ;

Navarro, Alejandro ;

Postel-Vinay, Sophie ;

Gainor, Justin F. ;

Johnson, Melissa ;

Dietrich, Jorg ;

James, Leonard P. ;

Clancy, Jill S. ;

Chen, Joseph ;

Martini, Jean-Francois ;

Abbattista, Antonello ;

Solomon, Benjamin J. .

LANCET ONCOLOGY, 2017, 18 (12) :1590-1599

[6] Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study [J].

Solomon, Benjamin J. ;

Bauer, Todd M. ;

Mok, Tony S. K. ;

Liu, Geoffrey ;

Mazieres, Julien ;

de Marinis, Filippo ;

Goto, Yasushi ;

Kim, Dong-Wan ;

Wu, Yi-Long ;

Jassem, Jacek ;

Lopez, Froylan Lopez ;

Soo, Ross A. ;

Shaw, Alice T. ;

Polli, Anna ;

Messina, Rossella ;

Iadeluca, Laura ;

Toffalorio, Francesca ;

Felip, Enriqueta .

LANCET RESPIRATORY MEDICINE, 2023, 11 (04) :354-366

[7] Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study [J].

Solomon, Benjamin J. ;

Besse, Benjamin ;

Bauer, Todd M. ;

Felip, Enriqueta ;

Soo, Ross A. ;

Camidge, D. Ross ;

Chiari, Rita ;

Bearz, Alessandra ;

Lin, Chia-Chi ;

Gadgeel, Shirish M. ;

Riely, Gregory J. ;

Tan, Eng Huat ;

Seto, Takashi ;

James, Leonard P. ;

Clancy, Jill S. ;

Abbattista, Antonello ;

Martini, Jean-Francois ;

Chen, Joseph ;

Peltz, Gerson ;

Thurm, Holger ;

Ou, Sai-Hong Ignatius ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2018, 19 (12) :1654-1667

[8] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models [J].

Zou, Helen Y. ;

Friboulet, Luc ;

Kodack, David P. ;

Engstrom, Lars D. ;

Li, Qiuhua ;

West, Melissa ;

Tang, Ruth W. ;

Wang, Hui ;

Tsaparikos, Konstantinos ;

Wang, Jinwei ;

Timofeevski, Sergei ;

Katayama, Ryohei ;

Dinh, Dac M. ;

Lam, Hieu ;

Lam, Justine L. ;

Yamazaki, Shinji ;

Hu, Wenyue ;

Patel, Bhushankumar ;

Bezwada, Divya ;

Frias, Rosa L. ;

Lifshits, Eugene ;

Mahmood, Sidra ;

Gainor, Justin F. ;

Affolter, Timothy ;

Lappin, Patrick B. ;

Gukasyan, Hovhannes ;

Lee, Nathan ;

Deng, Shibing ;

Jain, Rakesh K. ;

Johnson, Ted W. ;

Shaw, Alice T. ;

Fantin, Valeria R. ;

Smeal, Tod .

CANCER CELL, 2015, 28 (01) :70-81

← 1 →